GGrantIndex
Sort

53,477 grants matching addiction

Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain

$1,524,027
Pierre Riviere · Peptide Logic, Llc · R44 · FY2018 · DA

Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse

$1,522,479
Chang-Guo Zhan · University Of Kentucky · UH3 · FY2017 · DA

Medication Development for the Treatment of Alcohol Use Disorder

$1,521,805
Susan E. Bergeson · Texas Tech University Health Scis Center · U01 · FY2020 · AA

Non-pharmacological Options in postoperative Hospital-based And Rehabilitation pain Management (NOHARM) pragmatic clinical trial

$1,521,299
Andrea Lynne Cheville · Mayo Clinic Rochester · UH3 · FY2020 · AG

C57BI/6 Mouse Lines Expressing CRE-Recombinase in the Nervous System

$1,521,168
Ulrich Mueller · Scripps Research Institute, The · U01 · FY2008 · MH

Characterization of neuronal ensembles activated during drug-induced behavior

$1,519,811
Bruce Hope · National Institute On Drug Abuse · ZIA · FY2011 · DA

Yale/NIDA Neuroproteomics Center

$1,519,226
Kenneth Robert Williams · Yale University · P30 · FY2016 · DA

A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.

$1,519,167
Fredric Schiffer · Mindlight, Llc · R44 · FY2022 · DA

New approaches to addiction treatment

$1,518,640
David Epstein · National Institute On Drug Abuse · ZIA · FY2020 · DA

DRUGS OF ABUSE -- ROLE OF PROTEIN PHOSPHORYLATION

$1,517,475
Paul Greengard · Rockefeller University · P01 · FY2006 · DA

Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain

$1,516,765
A. Lenore Ackerman · University Of California Los Angeles · R61 · FY2024 · AT

Center for the Neurobiology of Addiction Treatment

$1,516,519
Steven R Childers · Wake Forest University Health Sciences · P50 · FY2009 · DA

Yale/NIDA Neuroproteomics Research Center

$1,514,432
Kenneth Robert Williams · Yale University · P30 · FY2008 · DA

Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)

$1,512,886
Khuanchai Supparatpinyo · Chiang Mai University · UM1 · FY2025 · AI

Corticostriatal mechanisms of action learning and habit formation

$1,512,160
David M Lovinger · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2018 · AA

Biological And Biochemical Characterization Of Sigma Receptors

$1,511,954
Tsung-Ping Ping Su · National Institute On Drug Abuse · ZIA · FY2022 · DA

Optimizing HIV-care-continuum engagement and outcomes among opioid users

$1,511,604
David Epstein · National Institute On Drug Abuse · ZIA · FY2018 · DA

Optimizing HIV-care-continuum engagement and outcomes among opioid users

$1,511,604
David Epstein · National Institute On Drug Abuse · ZIA · FY2019 · DA

OPTIMIZING RETENTION, DURATION AND DISCONTINUATION STRATEGIES FOR OPIOID USE DISORDER PHARMACOTHERAPY (CTN-0100). AUGUST 15, 2024 TO MARCH 31, 2028. N01DA-22-2253. TASK ORDER NO. 75N95024F00007 (TO23)

$1,510,879
Jennifer McCormack · The Emmes Company, Llc · N01 · FY2024 · DA

Genomewide Association Study of Cocaine Dependence in two Populations

$1,510,652
Joel Gelernter · Yale University · RC2 · FY2010 · DA

Innovative Approaches for Cocaine Pharmacotherapy

$1,510,494
Helen M Pettinati · University Of Pennsylvania · P50 · FY2009 · DA

Quantifying Exposure to Illicit Drugs & Psychosocial Stress in Real Time

$1,510,400
Kenzie Preston · National Institute On Drug Abuse · ZIA · FY2013 · DA

Quantifying Exposure to Illicit Drugs & Psychosocial Stress in Real Time

$1,509,833
Kenzie Preston · National Institute On Drug Abuse · ZIA · FY2012 · DA

Molecular Genetic Bases for Quit Success

$1,509,084
George R Uhl · National Institute On Drug Abuse · ZIA · FY2009 · DA

Synaptic Transmission: Modulation, Plasticity And Effects Of Drugs Of Abuse

$1,508,665
David M Lovinger · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2012 · AA